Vimarsana
Biggest News Aggregation in the World

Second Revision News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Second Revision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Second Revision Today - Breaking & Trending Today

DRINKING WATER QUALITY STANDARDS AND IMPLEMENTATION - Vimarsana News

DRINKING WATER QUALITY STANDARDS AND IMPLEMENTATION

Safe drinking-water is a human right. Through Sustainable Development Goal 6 – to ensure availability and sustainable management of water and sanitation for all by 2030 – the world reaffirmed its commitment to ensure safe drinking-water for all. Inadequate management of urban, industrial and

New Multiple Myeloma Staging Systems Outperform the Standard - Vimarsana News

New Multiple Myeloma Staging Systems Outperform the Standard

Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma - Vimarsana News

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd - Vimarsana News

Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd

Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma - Vimarsana News

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.